Latest News
Avalo Therapeutics Soars 34% on $375M Offering Following Positive Phase 2 HS Data
Avalo Therapeutics shares surged 34% after pricing a $375M public offering, following positive Phase 2 results for abdakibart in hidradenitis suppurativa. The company aims to fund Phase 3 development.
Klaviyo Shares Crash 30% as CFO Departure Overshadows Strong Q1 Results
Klaviyo shares fell 30% Wednesday as CFO Amanda Whalen's planned exit overshadowed a Q1 earnings beat and raised 2026 outlook.
TransMedics Shares Slide 23% on Earnings Miss, Despite Revenue Growth
TransMedics shares plunged 23% after Q1 adjusted earnings of $0.30 missed estimates, despite a 21% revenue increase. Profit fell sharply as costs rose.
Qualcomm Stock Surges Past $200 on AI Data Center Push and Hyperscaler Deal
Qualcomm shares rose 1.8% to $189.83 after hitting $200.34, driven by AI data center chip demand and a custom silicon deal with a top cloud operator.
Oscar Health Shares Surge 5% as Q1 Profit Doubles, 2026 Forecast Maintained
Oscar Health reported Q1 net income of $679M, more than double last year, with revenue up 53% to $4.65B. Shares rose 5.3% as the company reaffirmed its 2026 guidance.
POET Technologies Faces Class Action After Marvell Cancels Celestial AI Orders
POET Technologies is under a securities class action after Marvell canceled all Celestial AI purchase orders. Lead-plaintiff deadline is June 29. Stock at $9.385.
Palantir Drops Despite Record Revenue; Commercial Miss Triggers Selloff
Palantir shares slipped 1.4% to $134.04 despite record quarterly revenue of $1.63B. A $10M miss in U.S. commercial revenue triggered the decline, even as the company raised 2026 guidance.
IonQ Q1 Earnings: Quantum Growth Meets Market Reality
IonQ reports Q1 earnings with revenue of $49.8M and a loss of 46 cents per share. Shares rose 2.6% to $49.26 as investors weigh growth against risks.
Kraft Heinz Q1 Sales Beat Fuels CEO's Turnaround Strategy
Kraft Heinz beat Q1 sales estimates, sending shares up 3.6%. CEO Steve Cahillane's $600M turnaround plan gets an early boost as brand investment ramps up.
CVS Health Upgrades 2026 Profit View as Aetna Cost Controls Boost Q1 Results
CVS Health raised its 2026 profit outlook after a strong Q1, with revenue topping $100 billion and Aetna's medical benefit ratio improving to 84.6%. Shares surged 9%.
